Related Experiment Videos
Prolactin bioassay and hyperprolactinemia
C A Peabody1, P N Schultz, M D Warner
1Department of Psychiatry, University of Texas Medical School, Houston.
Journal of Endocrinological Investigation
|July 1, 1992
Summary
Dopamine agonist CV 205-502 effectively lowered prolactin (PRL) levels in hyperprolactinemia patients. However, the bioactivity of prolactin remained unchanged, suggesting treatment impacts overall levels but not intrinsic function.
Area of Science:
- Endocrinology
- Pharmacology
- Oncology
Background:
- Hyperprolactinemia is a condition characterized by elevated prolactin (PRL) levels.
- Pituitary adenomas are a common cause of hyperprolactinemia.
- Dopamine agonists are a primary treatment for hyperprolactinemia.
Purpose of the Study:
- To evaluate the effect of the dopamine agonist CV 205-502 on prolactin (PRL) levels and bioactivity in patients with hyperprolactinemia.
- To assess whether treatment with CV 205-502 alters the relative bioactivity of PRL.
Main Methods:
- The Nb2 rat lymphoma bioassay (BA) and radioimmunoassay (RIA) were used to measure PRL levels and bioactivity.
- Twenty-six subjects with hyperprolactinemia, including 17 with pituitary adenomas, were treated with CV 205-502.
- PRL levels and bioactivity were assessed before and after treatment.
Main Results:
- Radioimmunoassay (RIA) measured PRL levels significantly decreased after treatment with CV 205-502.
- The ratio of bioassay (BA) to RIA prolactin (PRL) remained unchanged, indicating stable relative bioactivity.
- Treatment with CV 205-502 effectively reduced overall PRL levels without altering its intrinsic biological activity.
Conclusions:
- Long-acting dopamine agonist CV 205-502 is effective in reducing serum prolactin levels in patients with hyperprolactinemia.
- The bioactivity of prolactin is not significantly affected by treatment with CV 205-502.
- This suggests that dopamine agonist therapy normalizes prolactin levels while preserving its functional capacity.